Dec 14 The U.S. Food and Drug Administration
said on Wednesday it had approved Pfizer Inc's Eucrisa
ointment to treat mild-to-moderate eczema, or atopic dermatitis,
in patients two years and older.
Atopic dermatitis is the most common of the many types of
eczema, typically beginning in childhood and possibly lasting
Pfizer bought Anacor Pharmaceuticals in a $5.2 billion deal
earlier this year to add the ointment to its portfolio.
(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by